Positive expression of transferrin receptor (TFR1) was associated with a higher risk of high-graded cancer (17/20 in patients with HGPC vs. 21/33 in patients with non-HGPC, p = 0.0023), whereas PTEN (p = 0.53), NF2 (p = 0.93), e-cadherin (p = 0.99) and CD49b (p = 0.38) status failed to achieve statistical significance. Here, TFRC is linked to cancer.